STOCK TITAN

InspireMD (NSPR) warned by Nasdaq over $1.00 bid price and delisting risk

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

InspireMD, Inc. received a notice from Nasdaq on July 17, 2026 that its common stock no longer meets the minimum $1.00 per share bid price requirement for continued listing on The Nasdaq Capital Market, based on 30 consecutive business days from June 3 through July 16, 2026.

The stock continues to trade on Nasdaq under the symbol NSPR and the notice has no immediate effect. InspireMD has 180 calendar days, until January 13, 2027, to regain compliance by achieving a closing bid of at least $1.00 for at least ten consecutive business days, a period Nasdaq may extend at its discretion.

If compliance is not regained, the company may qualify for an additional 180-day period if other listing standards are met and it notifies Nasdaq of a plan to cure the deficiency, potentially including a reverse stock split. Otherwise, its common stock could become subject to delisting, with a right to appeal. InspireMD plans to monitor its share price and evaluate options but provides no assurance it will regain compliance.

Positive

  • None.

Negative

  • Nasdaq minimum bid price non-compliance and delisting risk: InspireMD’s stock failed to meet the $1.00 minimum bid for 30 consecutive business days, triggering a Nasdaq notice, a 180-day cure period to January 13, 2027, and potential delisting if compliance is not restored or extended.

Filing Explained

A reverse stock split is identified only as a possible future cure, not an action taken in this filing; if effected, it would reduce the share count and raise the per-share price proportionally, without changing company value by the split itself.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice or transferred its listing to a different exchange.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Minimum bid price requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2) threshold for The Nasdaq Capital Market
Non-compliance observation period 30 consecutive business days Closing bid prices from June 3, 2026 through July 16, 2026
Initial compliance period 180 calendar days Period to regain bid price compliance ending January 13, 2027
Minimum compliant duration ten consecutive business days Days closing bid must be at least $1.00 per share within compliance period
Potential additional compliance period 180 calendar days Second period if other Nasdaq initial listing standards and conditions are satisfied
Nasdaq Listing Rule 5550(a)(2) regulatory
"not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)"
minimum bid price requirement financial
"requires listed securities to maintain a minimum bid price of $1.00 per share"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5810(c)(3)(A) regulatory
"In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a compliance period"
reverse stock split financial
"including, if necessary, by effecting a reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Nasdaq Hearings Panel regulatory
"the Company would have the opportunity to appeal Nasdaq’s determination to a Nasdaq Hearings Panel"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What Nasdaq compliance issue did InspireMD (NSPR) disclose?

InspireMD disclosed it received a Nasdaq notice on July 17, 2026 for failing the $1.00 minimum bid price requirement. The stock traded below $1.00 for 30 consecutive business days, putting its Nasdaq Capital Market listing at risk if compliance is not restored.

How long does InspireMD (NSPR) have to regain Nasdaq bid price compliance?

InspireMD has an initial 180-calendar-day compliance period, ending January 13, 2027, to restore its bid price to at least $1.00. The closing bid must meet or exceed $1.00 for ten consecutive business days during this window, subject to Nasdaq’s discretion.

Can InspireMD (NSPR) receive more time beyond January 13, 2027?

InspireMD may receive an additional 180-day compliance period if it meets all initial Nasdaq Capital Market listing standards other than bid price. It must also satisfy the market value of publicly held shares requirement and notify Nasdaq of plans to cure, potentially via reverse stock split.

What happens if InspireMD (NSPR) cannot regain Nasdaq compliance?

If InspireMD does not regain compliance and is ineligible for, or fails during, any additional period, Nasdaq may notify the company that its common stock will be subject to delisting. InspireMD would then have the opportunity to appeal to a Nasdaq Hearings Panel.

What actions is InspireMD (NSPR) considering to address the Nasdaq deficiency?

InspireMD states it will monitor the closing bid price and evaluate options to regain compliance. Potential actions include effecting a reverse stock split. However, the company cautions there is no assurance it will successfully regain or maintain Nasdaq listing compliance.

Does the Nasdaq notice immediately affect trading of InspireMD (NSPR) stock?

The Nasdaq notice has no immediate effect on trading. InspireMD’s common stock continues to trade on The Nasdaq Capital Market under the symbol NSPR while the company works within the defined compliance periods to address the bid price deficiency.
false 0001433607 0001433607 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 17, 2026

 

 

 

InspireMD, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-35731   26-2123838

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

6303 Waterford District Drive, Suite 215

Miami, Florida 33126

  33126
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (888) 776-6804

 

 

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   NSPR   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On July 17, 2026, InspireMD, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market. The Notice stated that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days from June 3, 2026 through July 16, 2026, the Company no longer satisfies the minimum bid price requirement.

 

The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on The Nasdaq Capital Market under the symbol “NSPR.”

 

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a compliance period of 180 calendar days, or until January 13, 2027, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the compliance period. Nasdaq may, in its discretion, require the Company to satisfy the minimum bid price requirement for a period in excess of ten consecutive business days before determining that the Company has demonstrated an ability to maintain long-term compliance.

 

If the Company does not regain compliance by January 13, 2027, the Company may be eligible for an additional 180-calendar-day compliance period, provided that it satisfies the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum bid price requirement, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, including, if necessary, by effecting a reverse stock split. If the Company is not eligible for an additional compliance period, or otherwise does not appear capable of curing the deficiency, Nasdaq may provide notice that the Company’s common stock will be subject to delisting. In that event, the Company would have the opportunity to appeal Nasdaq’s determination to a Nasdaq Hearings Panel.

 

The Company intends to actively monitor the closing bid price of its common stock and evaluate available options to regain compliance with the minimum bid price requirement, including, if necessary, effecting a reverse stock split. There can be no assurance that the Company will regain compliance with Nasdaq Listing Rule 5550(a)(2) during the initial compliance period or any additional compliance period, or that the Company will otherwise maintain compliance with the other Nasdaq listing requirements.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    INSPIREMD, INC.
       
Date: July 23, 2026 By: /s/ Marvin Slosman
    Name: Marvin Slosman
    Title: Chief Executive Officer

 

 

 

Filing Exhibits & Attachments

3 documents